Author

K. H. Tang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:scRNA-seq· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. G. Neel· 3 shared K.-K. Wong· 3 shared A. Khodadadi-Jamayran· 2 shared C. Fedele· 2 shared J. Deng· 2 shared J. Jen· 2 shared S. Li· 2 shared T. Chen· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. G. Neel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivMar 21, 2021

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

K. H. Tang, S. Li, A. Khodadadi-Jamayran…·B. G. Neel

This study shows that combining SHP2 and CXCR1/2 inhibitors enhances anti-tumor T cell responses in NSCLC by reducing immunosuppressive gMDSCs and promoting effector T cells.

DOI 10.1158/2159-8290.cd-21-0369

mouseproteomics

𝕏 PostBluesky

Cancer BiologyJournal of Experimental MedicinePeer-reviewedOct 8, 2020

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors

C. Fedele, S. Li, K. W. Teng…·B. G. Neel

This study shows that combining SHP2 inhibitors with KRASG12C inhibitors enhances efficacy in PDAC and NSCLC by overcoming resistance and remodeling the tumor microenvironment.

DOI 10.1084/jem.20201414

mouseproteomics

𝕏 PostBluesky

Cancer BiologybioRxivAug 28, 2020

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

C. A. Chang, J. Jen, S. Jiang…·B. G. Neel

This study identifies drug-tolerant persisters (DTPs) in HER2+ breast cancer and reveals their origins and vulnerabilities to TKI resistance.

DOI 10.1158/2159-8290.cd-20-1265

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivMay 10, 2019

Distinct cancer-associated fibroblast states drive clinical outcomes in high-grade serous ovarian cancer and are regulated by TCF21

A. Hussain, V. Voisin, S. Poon…·L. Ailles

This study identifies two distinct cancer-associated fibroblast subtypes in high-grade serous ovarian cancer and shows their differential impact on patient outcomes and tumor progression.

DOI 10.1084/jem.20191094

humanscRNA-seq

𝕏 PostBluesky